Skip to main content

Table 1 Baseline characteristics of children enrolled in the trial, by randomization group

From: A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections

Characteristic

Group A

treatment, 3 months (n = 123)

Group B

placebo

(n = 124)

Group C

treatment, 6 months

(n = 41)

N

%

n

%

n

%

Sex

 Male

72

58.5

81

65.3

26

63.4

 Female

51

41.5

43

34.7

15

36.6

Age at baseline (years)

 1–2

63

51.2

46

37.1

16

39.0

 3–4

41

33.3

50

40.3

12

29.3

 5–6

19

15.5

28

22.6

13

31.7

 Mean ± SD

3.6 ± 1.6

 

3.7 ± 1.5

 

3.8 ± 1.7

 

Ethnic group

 Caucasian

104

84.5

102

82.3

36

87.8

 Any other

19

15.5

22

17.7

5

12.2

Residence

 Milan City

59

48.0

72

58.1

26

63.4

 Outside Milan

64

52.0

52

41.9

15

36.6

Education (parents)a

 Primary/secondary

9

7.3

9

7.4

4

9.8

 High school degree (at least one parent)

60

48.8

43

35.2

14

34.1

 University degree (at least one parent)

54

43.9

70

57.4

23

56.1

Passive smoking (from parents)

 No

81

66.4

89

71.8

26

63.4

 Yes (at least one parent)

41

33.6

35

28.2

15

36.6

No. of siblings

 0

28

22.8

31

25.0

13

31.7

 1

75

61.0

73

58.9

20

48.8

 2+

20

16.3

20

16.1

8

19.5

Attending nursery/primary school

 No

18

14.6

9

7.3

5

12.2

 Yes

105

85.4

115

92.7

36

87.8

History of atopy

 No

96

78.1

95

76.6

32

78.1

 Yes

27

21.9

29

23.4

9

21.9

History of recurrent wheezing

 No

105

85.4

103

83.1

35

85.4

 Yes

18

14.6

21

16.9

6

14.6

  1. No statistically significant differences were detected between groups
  2. aThe sums may not add up to the total because of missing values